Atea Pharmaceuticals (AVIR) Depreciation & Amortization (CF) (2020 - 2022)

Atea Pharmaceuticals has reported Depreciation & Amortization (CF) over the past 3 years, most recently at $104000.0 for Q4 2022.

  • Quarterly results put Depreciation & Amortization (CF) at $104000.0 for Q4 2022, up 1385.71% from a year ago — trailing twelve months through Dec 2022 was $260000.0 (up 796.55% YoY), and the annual figure for FY2025 was $416000.0, changed 0.0%.
  • Depreciation & Amortization (CF) for Q4 2022 was $104000.0 at Atea Pharmaceuticals, down from $106000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for AVIR hit a ceiling of $106000.0 in Q3 2022 and a floor of $4000.0 in Q1 2020.
  • Median Depreciation & Amortization (CF) over the past 3 years was $7000.0 (2021), compared with a mean of $25666.7.
  • Peak annual rise in Depreciation & Amortization (CF) hit 1414.29% in 2022, while the deepest fall reached 0.0% in 2022.
  • Atea Pharmaceuticals' Depreciation & Amortization (CF) stood at $6000.0 in 2020, then increased by 16.67% to $7000.0 in 2021, then surged by 1385.71% to $104000.0 in 2022.
  • The last three reported values for Depreciation & Amortization (CF) were $104000.0 (Q4 2022), $106000.0 (Q3 2022), and $43000.0 (Q2 2022) per Business Quant data.